| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18427147 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 118 journal articles in the PubMed database | Email to a friend | | |
| Greenspan SL, Brufsky A, Lembersky BC, et al.
Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. [JOURNAL ARTICLE]
J Clin Oncol 2008 Apr 21.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Välimäiki MJ, Farrerons-Minguella J, Halse J, et al.
Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: A multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial. [Journal Article]
Clin Ther 2007 Sep; 29(9):1937-49.
Abstract | Full Citation | | Greenspan SL, Bhattacharya RK, Sereika SM, et al.
Prevention of Bone Loss in Survivors of Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. [JOURNAL ARTICLE]
J Clin Endocrinol Metab 2006 Oct 17.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Delmas PD, Balena R, Confravreux E, et al.
Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. [Clinical Trial, Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial]
J Clin Oncol 1997 Mar; 15(3):955-62.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Leung JY, Ho AY, Ip TP, et al.
The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
Bone 2005 Feb; 36(2):358-64.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Hooper MJ, Ebeling PR, Roberts AP, et al.
Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. [Journal Article, Multicenter Study, Randomized Controlled Trial]
Climacteric 2005 Sep; 8(3):251-62.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Mok CC, Tong KH, To CH, et al.
Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial. [JOURNAL ARTICLE]
Osteoporos Int 2007 Nov 24.
Abstract | Full Citation | Find Related Articles | | Confavreux CB, Fontana A, Guastalla JP, et al.
Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. [JOURNAL ARTICLE]
Bone 2007 Jun 16.
Abstract | Full Citation | Find Related Articles | | Yonehara Y, Iwamoto I, Kosha S, et al.
Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients. [Journal Article]
J Obstet Gynaecol Res 2007 Oct; 33(5):696-9.
Abstract | Full Citation |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
